{"id":674683,"date":"2026-05-16T12:37:05","date_gmt":"2026-05-16T12:37:05","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/674683\/"},"modified":"2026-05-16T12:37:05","modified_gmt":"2026-05-16T12:37:05","slug":"csl-the-100-billion-downfall-of-an-aussie-giant","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/674683\/","title":{"rendered":"CSL: The $100 billion downfall of an Aussie giant"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" alt=\"Colin Kruger\" data-testid=\"author-avatar-image\" height=\"64\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/02\/0ec7187b93286dfb0f0abbff3fe1e9df3e81e2d6.png\"  width=\"64\" class=\"sc-9a01536c-0 libeSR\"\/>Save<\/p>\n<p class=\"sc-d1b14060-4 JmUoF\">You have reached your maximum number of saved items.<\/p>\n<p>Remove items from your <a href=\"https:\/\/www.smh.com.au\/goodfood\/saved\" class=\"sc-3f16ee48-12 sc-d1b14060-2 jyLmZI iQLtAb\" rel=\"nofollow noopener\" target=\"_blank\">saved list<\/a> to add more.<\/p>\n<p>AAA<\/p>\n<p>CSL investors had already torched tens of billions of dollars of wealth on the biomedical giant before the year had even started, and a sense of panic must have set in when its chief executive, Dr Paul McKenzie, abruptly resigned the day before its half-year results announcement in February.<\/p>\n<p>How much worse could it get?<\/p>\n<p><img decoding=\"async\" alt=\"CSL chairman Brian McNamee, who formerly ran the company for years as CEO, is presiding over a company in steep decline.\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/ab94ded5a05a6d2dc645249cc2b67ad0986db77b711caaffd9135d552e7fe051.jpeg\"  class=\"sc-d34e428-1 ldCIuB\"\/>CSL chairman Brian McNamee, who formerly ran the company for years as CEO, is presiding over a company in steep decline.Matt Willis<\/p>\n<p>Trump\u2019s war on big pharma\u2019s pricing power in the US, and weakness on the vaccine front from COVID fatigue and vaccine scepticism from his health secretary Robert F. Kennedy Jr, <a class=\"inline-link\" href=\"https:\/\/www.smh.com.au\/business\/companies\/trump-s-tariffs-and-anti-vaxxer-clash-with-australia-s-130b-health-giant-20250819-p5mo4s.html\" rel=\"nofollow noopener\" target=\"_blank\">had already driven the share price down<\/a> from $270 to $180.<\/p>\n<p>But the man who orchestrated CSL\u2019s dizzying global success, former chief executive and current chairman Brian McNamee, was on the conference call to calm investor nerves about the abrupt leadership change and show his confidence that its performance would soon be back on track.<\/p>\n<p>\u201cI can assure you, this is still a very strong organisation. It generates very strong cash flows as a business. It has significant unmet medical needs in much of its portfolio,\u201d he told them.<\/p>\n<p>Related Article<a href=\"https:\/\/www.smh.com.au\/business\/companies\/88b-bloodbath-shows-trump-is-not-the-only-problem-for-aussie-pharma-giant-20260511-p5zvlu.html\" tabindex=\"-1\" class=\"sc-cba76dee-0 hdiTqm\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" alt=\"Under pressure: CSL chairman Brian McNamee.\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/1778935019_78_2deceda9d9b41a70bf275ba3db689f1609ee4470.jpeg\"  class=\"sc-d34e428-1 ioInpc\"\/><\/a><\/p>\n<p>The calm assurance may have fallen a little flat given CSL had just botched the announcement of McKenzie\u2019s abrupt retirement from the group.<\/p>\n<p>A misjudgment of the timing meant the stock was not in a trading halt when the announcement was made. It dropped amid chaotic trading, which added billions of dollars of losses to the tens of billions investors had already absorbed since the cycle of downgrades began in August last year.<\/p>\n<p>Last year, the ASX had effectively extended the market trading window by 10 minutes. It is not something that an $80 billion market colossus should have missed.<\/p>\n<p>On the conference call which followed, McNamee repeatedly mentioned the need for \u201curgency\u201d as well as the need to find the right CEO for the growth path ahead.<\/p>\n<p>McKenzie \u2013 who attempted to address performance issues last year by cutting staff and consolidating its R&amp;D operations \u2013 no longer fitted the bill.<\/p>\n<p>\u201cWe, in discussion with Paul, recognised he didn\u2019t have the skills that we wanted for the future,\u201d McNamee said.<\/p>\n<p><img decoding=\"async\" alt=\"CSL Chairman Brian McNamee (speaking) and CEO Paul McKenzie at the firm\u2019s last AGM. McKenzie would be gone within months.\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/1ad2651a6726ebb46fac4c5cf901a73558012aef.jpeg\"  class=\"sc-d34e428-1 ldCIuB\"\/>CSL Chairman Brian McNamee (speaking) and CEO Paul McKenzie at the firm\u2019s last AGM. McKenzie would be gone within months.Eamon Gallagher<\/p>\n<p>McNamee sold investors on one saving grace amid the chaos.<\/p>\n<p>CSL would be parachuting a company veteran who helped shape the group into a global giant, Gordon Naylor.<\/p>\n<p>Related Article<a href=\"https:\/\/www.smh.com.au\/business\/companies\/the-good-the-bad-and-the-very-ugly-of-profit-season-20260211-p5o1bw.html\" tabindex=\"-1\" class=\"sc-cba76dee-0 hdiTqm\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" alt=\"CBA boss Matt Comyn, Helen Lofthouse of the ASX and CSL\u2019s former chief Paul McKenzie. \" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/02\/38cfa49058f0a365c9407cdc7dc77395d87ab4b9.jpeg\"  class=\"sc-d34e428-1 ioInpc\"\/><\/a><\/p>\n<p>This would ensure the company\u2019s transformation continues with the urgency the board demands while also allowing them the time to find the right replacement, which may not happen until next year.<\/p>\n<p>Naylor and McNamee took every effort to impress on investors that there was no need for concern, even when pressed by an analyst on whether the growth outlook had materially changed.<\/p>\n<p>\u201cOur fundamentals haven\u2019t changed, and I think the outlook for our core products haven\u2019t changed,\u201d McNamee said.<\/p>\n<p>The answer that stands out as ominous in retrospect was Naylor\u2019s response to a question on whether he would be scrutinising its largest business \u2013 plasma \u2013 which he used to run.<\/p>\n<p>\u201cI think it\u2019s probably a bit too early for me to be doing diagnosis, but I\u2019d just say that we will be looking very closely at all parts of the operation and answering questions like that one.\u201d<\/p>\n<p><img decoding=\"async\" alt=\"US President Donald Trump (right) and Robert F. Kennedy Jr created a storm of turbulence for groups like CSL last year.\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/1f9cbc289e7c0bd36838c27b60700824beda9016.jpeg\"  class=\"sc-d34e428-1 ldCIuB\"\/>US President Donald Trump (right) and Robert F. Kennedy Jr created a storm of turbulence for groups like CSL last year.Bloomberg<\/p>\n<p>The following day, the carnage continued afresh with December half-year results that fell short of market estimates and included $1.5 billion in writedowns.<\/p>\n<p>The stock plunged to an eight-year low of $150 but Naylor and CSL\u2019s new chief financial officer Ken Lim stuck to the growth outlook put in place by their predecessors.<\/p>\n<p>CSL was still expecting revenue growth of 2-3 per cent and underlying earnings growth of around 4 to 7 per cent for the financial year ending this June 30. It implicitly included what Lim described as \u201can ambitious growth plan\u201d for the current half year.<\/p>\n<p>Analysts were sceptical.<\/p>\n<p>\u201cIt faces the daunting prospect of hiring a new CEO to reinvigorate a lacklustre growth outlook in the face of headwinds on multiple fronts,\u201d Bell Potter\u2019s Thomas Wakim said in one of the most critical notes on its downgrade.<\/p>\n<p>It took 90 days for Naylor to finish looking under the hood of the business he had known so well \u2013 before retiring in 2019 \u2013 and ring the alarm bells.<\/p>\n<p>The big downgrade that the market had feared in February when McKenzie was dumped finally hit this week and <a class=\"inline-link\" href=\"https:\/\/www.smh.com.au\/business\/companies\/88b-bloodbath-shows-trump-is-not-the-only-problem-for-aussie-pharma-giant-20260511-p5zvlu.html\" rel=\"nofollow noopener\" target=\"_blank\">sent the stock plunging<\/a>, taking with it any confidence investors had in the group.<\/p>\n<p>Naylor confirmed there would be no June miracle. Revenue and underlying profit would drop this year, not rise.<\/p>\n<p>Related Article<a href=\"https:\/\/www.smh.com.au\/business\/companies\/how-trump-s-antivaxxers-helped-trigger-aussie-giant-s-50b-implosion-20251030-p5n6i9.html\" tabindex=\"-1\" class=\"sc-cba76dee-0 hdiTqm\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" alt=\"President Trump and Robert F. Kennedy at a Make America Healthy Again event in May.\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/02\/7504ed0aa63a19f6349ffbd10c8d84995b27e132.jpeg\"  class=\"sc-d34e428-1 ioInpc\"\/><\/a><\/p>\n<p>\u201cThe market was blindsided by full-year guidance well below (consensus) and the headwinds appeared structural,\u201d was the brutal verdict from Morningstar\u2019s Shane Ponraj.<\/p>\n<p>\u201cIf there is a silver lining to this dark cloud, it is that CSL is clearing the decks and, importantly, admitting mistakes,\u201d Ponraj said, adding that the massive writedown reflects a \u201ccollision with reality.\u201d<\/p>\n<p>What Naylor discovered was that most of CSL\u2019s global business was facing a toxic mix of market softness or increased competition. This included the core business that made the group a global giant \u2013 plasma and its related therapy drugs \u2013 which generate 70 per cent of its earnings.<\/p>\n<p>One fund manager who requested anonymity to speak freely about CSL\u2019s woes said this third downgrade in less than a year raises questions about the executive team and board: \u201cHow well do you know your business?\u201d he asked.<\/p>\n<p>\u201cI don\u2019t think they know what\u2019s going on.\u201d<\/p>\n<p>CSL has been caught napping on its core plasma business in its largest market, the US, losing market share to rivals like Grifols, and it is taking a $US300 million hit to \u201cnormalise\u201d inventory levels in that market.<\/p>\n<p>Meanwhile in China, CSL\u2019s albumin business \u2013 a plasma-based treatment \u2013 is facing hospital budget restrictions that are lowering price and demand and warranted another $US200 million hit.<\/p>\n<p>There was also a $5 billion writedown in the value of its Vifor business, which specialises in treating iron deficiency and kidney-related diseases.<\/p>\n<p>CSL acquired the group for $16 billion cash in 2022 but clearly overpaid for a business that is now being eaten by generic rivals for its iron-based products in both Europe and the US.<\/p>\n<p>The only business to emerge unscathed was the vaccine business, Seqirus, which had its spin-off plans postponed by a shock fall in its US business last year which kicked off CSL\u2019s downgrades.<\/p>\n<p><img decoding=\"async\" alt=\"CSL has experienced trouble with its vaccine business and plasma business in the US, its biggest market.  \" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/69e44b63d0598cc0822cd00dd9615a36aa051188.jpeg\"  class=\"sc-d34e428-1 ldCIuB\"\/>CSL has experienced trouble with its vaccine business and plasma business in the US, its biggest market.  Bloomberg<\/p>\n<p>Brokers slashed earnings and revenue guidance for the coming years with some concerned about the growth profile for the business, including plasma.<\/p>\n<p>Anja Samardzic, a portfolio manager at AllianceBernstein with an academic background in medical science sums it up neatly: \u201cI think the market was quite concerned that plasma market growth had fallen away, and so that there was something wrong with plasma market fundamentals.\u201d<\/p>\n<p>She thinks the problem is the complacency that set in within CSL, which for so long had been the dominant force in a growing market and was unable to respond when traditionally weak rivals decided to aggressively target market share.<\/p>\n<p>She says all the data points to growth continuing in the mid to high single digits, as CSL has said. And the group remains the lowest-cost, highest-quality player.<\/p>\n<p>\u201cThey just need to turn the commercial execution around a bit. They don\u2019t have to grow (market share) here. They just have to stop losing it,\u201d she says.<\/p>\n<p>\u2018If there is a silver lining to this dark cloud, it is that CSL is clearing the decks and, importantly, admitting mistakes.\u2019<\/p>\n<p>Morningstar\u2019s Shane Ponraj<\/p>\n<p>CSL\u2019s valuation is now trading at a significant discount to its peers and the ASX200, but some analysts see this as warranted given the issues around management credibility and performance.<\/p>\n<p>\u201cWe think a discount is warranted for CSL considering the declining underlying earnings outlook across FY26-27, the lack of stable management, and a series of credibility hits following several disappointing results\/trading updates,\u201d Bell Potter\u2019s Wakim said.<\/p>\n<p>Related Article<a href=\"https:\/\/www.smh.com.au\/business\/companies\/rfk-jr-s-policies-contribute-to-10-billion-hit-to-one-of-australia-s-biggest-companies-20260211-p5o1ap.html\" tabindex=\"-1\" class=\"sc-cba76dee-0 hdiTqm\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" alt=\"US Health Secretary Robert F. Kennedy Jr: Having an anti-vaxxer in charge of America\u2019s health system has been one of the factors hitting CSL\u2019s performance.   \" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/05\/ea3504ca697ac148271b1401c9117f29e107a6d935c5de9463cfe945217374dc.jpeg\"  class=\"sc-d34e428-1 ioInpc\"\/><\/a><\/p>\n<p>The solace for investors is that McNamee is right about one thing, the business and the industry outlook are still intact. Earnings have not actually crumpled despite the massive loss of shareholder wealth, which reached $105 billion over the last two years from peak to trough this week.<\/p>\n<p>It is the multiple that the market is prepared to pay for these earnings that has crumpled, reflecting the loss of confidence in management as its growth path faltered.<\/p>\n<p>According to Macquarie Equities, the stock traded at a multiple of more than 44 times earnings during COVID. Its market value is now 10 times its earnings.<\/p>\n<p>As Samardzic says, it\u2019s not a matter of having to execute perfectly on sales growth.<\/p>\n<p>\u201cThey just need to rebuild credibility with the market \u2026 execute and rebuild credibility.\u201d<\/p>\n<p>The Business Briefing newsletter delivers major stories, exclusive coverage and expert opinion. <a class=\"inline-link\" href=\"https:\/\/www.smh.com.au\/link\/follow-20170101-p56j4t\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">Sign up to get it every weekday morning<\/a>.<\/p>\n<p>Save<\/p>\n<p class=\"sc-d1b14060-4 JmUoF\">You have reached your maximum number of saved items.<\/p>\n<p>Remove items from your <a href=\"https:\/\/www.smh.com.au\/goodfood\/saved\" class=\"sc-3f16ee48-12 sc-d1b14060-2 jyLmZI iQLtAb\" rel=\"nofollow noopener\" target=\"_blank\">saved list<\/a> to add more.<\/p>\n<p><img decoding=\"async\" alt=\"Colin Kruger\" data-testid=\"author-avatar-image\" height=\"40\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/01\/1768176256_961_0ec7187b93286dfb0f0abbff3fe1e9df3e81e2d6.png\"  width=\"40\" class=\"sc-9a01536c-0 libeSR\"\/><a class=\"sc-cba76dee-0 hdiTqm sc-b5b9fd03-2 jcGta-D\" href=\"https:\/\/www.smh.com.au\/by\/colin-kruger-hve6c\" rel=\"nofollow noopener\" target=\"_blank\">Colin Kruger<\/a> is a senior business reporter for the Sydney Morning Herald and The Age.Connect via <a class=\"sc-cba76dee-0 hdiTqm sc-b5b9fd03-5 czsZcI\" href=\"https:\/\/www.smh.com.au\/business\/companies\/mailto:ckruger@smh.com.au\" rel=\"nofollow noopener\" target=\"_blank\">email<\/a>.From our partners<\/p>\n","protected":false},"excerpt":{"rendered":"Save You have reached your maximum number of saved items. Remove items from your saved list to add&hellip;\n","protected":false},"author":2,"featured_media":674684,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[64,63,99],"class_list":["post-674683","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-au","tag-australia","tag-business"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/674683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=674683"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/674683\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/674684"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=674683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=674683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=674683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}